Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
纵向组学数据和临床前治疗表明,蛋白酶体抑制剂卡非佐米可作为伊布替尼耐药性慢性淋巴细胞白血病(CLL)的治疗方法。
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-56318-7
Arseni, Lavinia; Sigismondo, Gianluca; Yazdanparast, Haniyeh; Hermansen, Johanne U; Mack, Norman; Ohl, Sibylle; Kalter, Verena; Iskar, Murat; Kalxdorf, Mathias; Friedel, Dennis; Rettel, Mandy; Paul, Yashna; Ringshausen, Ingo; Eldering, Eric; Dubois, Julie; Kater, Arnon P; Zapatka, Marc; Roessner, Philipp M; Tausch, Eugen; Stilgenbauer, Stephan; Dietrich, Sascha; Savitski, Mikhail M; Skånland, Sigrid S; Krijgsveld, Jeroen; Lichter, Peter; Seiffert, Martina